Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) has filed its Monthly Return for the period ended 31 October 2026, confirming stable capital structure and continued compliance with Hong Kong Stock Exchange (HKEX) public-float requirements.
Authorised / Registered Capital • Ordinary H-shares: 154.33 million authorised shares at an RMB 0.20 par value, equal to RMB 30.87 million. No change from the previous month. • Domestic ordinary shares: 171.65 million authorised shares at an RMB 0.20 par value, equal to RMB 34.33 million. No change from the previous month. • Combined authorised share capital remained unchanged at RMB 65.20 million.
Issued and Treasury Shares • H-shares in issue (excluding treasury): 151.54 million; treasury H-shares: 2.79 million; total H-shares issued: 154.33 million. • Domestic shares in issue: 171.65 million with no treasury stock. • No issuance, cancellation, conversion or repurchase activities occurred during October, leaving total issued shares steady at 325.98 million.
Public Float Compliance • Bao Pharma affirmed adherence to the HKEX minimum public-float threshold of 25% for its H-share class as of 31 October 2026.
Corporate Confirmation • The company declared that all regulatory, legal and listing-rule obligations related to its share capital remain fully satisfied, as confirmed by Executive Director Liu Yanjun in the submission dated 2 November 2026.
Comments